|Bid||209.58 x 1100|
|Ask||214.03 x 800|
|Day's range||209.90 - 214.49|
|52-week range||173.45 - 371.16|
|Beta (5Y monthly)||1.13|
|PE ratio (TTM)||48.24|
|Earnings date||07 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||242.79|
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.